ABSTRACT
An open comparative, prospective and randomized study was carried out to evaluate the efficacy and safety of quinfamide and etofamide in the treatment of intestinal amebiasis. This study evaluate two populations: children (1-16 years) and adults (17-80 years). The drugs used were quinfamide at doses of 4.3 mg/kg b.i.d. in children, and 100 mg t.i.d. adults both for one day; and etofamide at doses of 200 mg t.i.d. in children and 500 mg b.i.d. in adults both for three days. A total of 110 patients were included, 54 in the quinfamide group and 56 in the etofamide group. No significant difference between groups in baseline demographics characteristics were observed. Global healing rate for quinfamide group was 87% and for etofamife group was 76.8% (p = 0.0696). This difference was similar considering both group of populations. It is concluded that the therapeutical response was better for the quinfamide group than for the etofamide group. Both drugs have the same safety profile.
Subject(s)
Acetamides/therapeutic use , Amebicides/therapeutic use , Dysentery, Amebic/drug therapy , Quinolines/therapeutic use , Adolescent , Adult , Aged , Aged, 80 and over , Child , Child, Preschool , Humans , Infant , Mexico , Middle AgedABSTRACT
Se llevó a cabo un estudio abierto, comparativo, prospectivo y al azar para evaluar la eficacia y seguridad de la quinfamida y de la etofamida en el tratamiento de pacientes con amibiasis intestinal. Se evaluaron dos poblaciones de niños (1-16 años) y adultos (17-80 años). Las dosis utilizadas fueron: Quinfamida en niños 4.3 mg/Kg 2 veces al día y en adultos 100 mg. cada 8 horas, en ambos por día; y Etofamida en niños 200 mg 3 veces al día y en adultos 500 mg. cada 12 horas, en ambos durante 3 días. Se incluyeron 110 pacientes, 54 en el grupo de la quinafamida y 56 en el de la etofamida. No se observaron diferencias significativas en las características demogr ficas basales. Al finalizar el tratamiento se observó una tasa de curación global para la quinfamida de 87 por ciento y de 76.8 por ciento para la etofamida (p = 0.0696). Separada por poblaciones se mantuvo la diferencia porcentual. Se concluye que la respuesta terapéutica fue mejor para la quinfamida y que el perfil de seguridad de ambos f rmacos es aceptable. (AU)
Subject(s)
Comparative Study , Humans , Adult , Child , Child, Preschool , Infant , Middle Aged , Adolescent , Aged , Dysentery, Amebic/drug therapy , Amebicides/therapeutic use , Amebicides/administration & dosage , Treatment Outcome , Drug Evaluation , Statistics, Nonparametric , Random Allocation , Mexico , Aged, 80 and overABSTRACT
Se llevó a cabo un estudio abierto, comparativo, prospectivo y al azar para evaluar la eficacia y seguridad de la quinfamida y de la etofamida en el tratamiento de pacientes con amibiasis intestinal. Se evaluaron dos poblaciones de niños (1-16 años) y adultos (17-80 años). Las dosis utilizadas fueron: Quinfamida en niños 4.3 mg/Kg 2 veces al día y en adultos 100 mg. cada 8 horas, en ambos por día; y Etofamida en niños 200 mg 3 veces al día y en adultos 500 mg. cada 12 horas, en ambos durante 3 días. Se incluyeron 110 pacientes, 54 en el grupo de la quinafamida y 56 en el de la etofamida. No se observaron diferencias significativas en las características demogr ficas basales. Al finalizar el tratamiento se observó una tasa de curación global para la quinfamida de 87 por ciento y de 76.8 por ciento para la etofamida (p = 0.0696). Separada por poblaciones se mantuvo la diferencia porcentual. Se concluye que la respuesta terapéutica fue mejor para la quinfamida y que el perfil de seguridad de ambos f rmacos es aceptable.
Subject(s)
Humans , Adult , Child , Child, Preschool , Infant , Middle Aged , Adolescent , Amebicides/therapeutic use , Dysentery, Amebic/drug therapy , Aged, 80 and over , Amebicides/administration & dosage , Drug Evaluation , Mexico , Random Allocation , Statistics, Nonparametric , Treatment OutcomeABSTRACT
OBJECTIVE: A ten year prolective and multicentre study of cancer of the Digestive Tract aims to evaluate the variations on frequency and to identify risk factors. METHODS: Ten hospitals are participating five in Mexico City and five in other states. Data were obtained through the hospitals files and specially designed questionnaires, the latter mainly diet and habits oriented. RESULTS: Through this ten years in the 4,715 cases studied we can appreciate a decreasing tendency of the carcinoma of the stomach (GC) that has been the most frequent until 1984 in the general group General Hospital and Instituto Nacional de la Nutrición. Since then and up to date, first place in frequency in shared between the stomach and colorectal carcinoma (CRC). CRC has been increasing even in the General Hospital in which GC was very high. Eighth years ago we found that people in those hospitals in which GC was high the diet was poor in proteins, fat A and C vitamin. People in those hospitals with high frequency of CRC had diet high in protein, fat and low in fiber. A new study on diet is ongoing. Gallbladder and biliary tract carcinoma has been increasing in all the hospitals. A high O blood group was found in the Juarez Hospital in which gallbladder carcinoma was the highest. O group is highest in the indian people. Cancer of the gallbladder is very high in Pimas and Navajos indians. A plan to study litogenic index and culture of salmonella is going to be practiced in bile from normal and gallbladder carcinoma. Concerning habits, tobacco and alcohol consumption are most frequent in cancer of the esophagus and pancreas. Also coffee consumption is high in the latter. CONCLUSIONS: Along this 10-year study, the frequency of gastric cancer has been decreasing. Instead, the frequencies of colo rectal and biliary tract cancers have been increasing. Variations in frequencies correlated with the composition of the diet, fiber consumption habits and racial characteristics of the different groups.